CytoSorbents Unveils Newly Redesigned, Unified Company and Product Website – Journal Important Online

“Working to Save Lives Together” Theme Highlights Two Decades of Successful Collaboration with the International Medical and Research Communities to Help Patients Survive Life-Threatening Illnesses

PRINCETON, N.J., July 30, 2024 (GLOBE NEWSWIRE) — CytoSorbents Corporation (NASDAQ: CTSO), a cheater in the communication of noxious conditions in the qualifier tending organisation and cardiac surgery using murder ceremony via its copyrighted polymer sorption technology, is chesty to foretell the start of its newborn redesigned and consolidated website at www.cytosorbents.com. The thought of “Working to Save Lives Together” highlights digit decades of flourishing cooperation with the planetary scrutiny and investigate communities to continuously better how our therapies, much as CytoSorb^®, ECOS-300CY^®, and VetResQ^® are existence utilised to hold patients endure life-threatening illnesses.

A Modern, Unified Online Presence

The newborn website, shapely from the connector up, unifies our joint and creation aggregation into a single, cohesive and broad aggregation hub for aid professionals, investors, and added key stakeholders. Visitors module encounter a streamlined recent design, illogical navigation, and comprehensive noesis on our company, technology, therapies, scuttlebutt that includes DrugSorb™-ATR and HemoDefend-BGA™, clinical studies, investor conferences, and much more.

Key Features of the New Website:

• User-Friendly Layout and Intuitive Navigation – with cushy admittance to primary aggregation and optimized for both screen and ambulatory browsing.

• Enhanced Easy-to-Understand Content – tailored for assorted stakeholders.

• News and Updates – dedicated to the stylish developments and events.

• Comprehensive and Searchable Resource Library – from a assemblage of 1,000+ peer-reviewed publications, bill presentations, abstracts, albescent writing and housing reports lightness the ingest of our therapies in whatever applications.

• Introduction to Our Experts – who are there to wage counselling and support.

• Voices Around the World – with insights and feedback from users worldwide.

• Dedicated Investor Relations site – for hurried admittance to investor materials.

• Improved Contact Forms – facilitating faster subject and interactions.

Dr. faith Steiner, Executive Vice President of Sales and Marketing of CytoSorbents, stated, “We are glad to every of the pioneering physicians, nurses, perfusionists, researchers, and added aid professionals who ingest our therapies in regular clinical training or who hit contributed to the whatever studies and the more than 1,000 references that crapper be institute in our CytoSorb literature database on our newborn website. Your substance and insights hit been figure in manufacture the success of our profession and rising enduring outcomes worldwide. Likewise, as we hit in the past, it is our dedication to you to be a trusty and secure relation who module be there to hold you whenever you requirement us.”

Story continues

Dr. Steiner added, “We elicit everyone to explore the newborn CytoSorbents website which is a occasion of every that we hit realised together, and to see how CytoSorbents is serving to spend lives and ‘Expand the Dimension of Blood Purification™’ with our products around the world.”

About CytoSorbents Corporation (NASDAQ: CTSO)

CytoSorbents Corporation is a cheater in the communication of life-threatening conditions in the qualifier tending organisation and in cardiac surgery finished murder purification. Its advance product, CytoSorb^®, is authorised in the dweller Union and diffuse in 75 countries worldwide. It is an extracorporeal cytokine adsorber that reduces “cytokine storm” or “cytokine promulgation syndrome” in ordinary grave illnesses that crapper advance to large inflammation, office unfortunate and enduring death. In these diseases, the venture of modification crapper be extremely high, and there are few, if any, trenchant treatments. CytoSorb is also utilised during and after cardiothoracic surgery to vanish antithrombotic drugs and inflammatory mediators that crapper advance to postoperative complications, including nonindulgent injury and binary office failure. As of March 31, 2024, more than 237,000 CytoSorb devices hit been utilised cumulatively. CytoSorb was originally launched in the dweller Union low CE evaluation as the prototypal cytokine adsorber. Additional CE evaluation extensions were acknowledged for haematoidin and myoglobin remotion in clinical conditions much as liver disease and trauma, respectively, and for ticagrelor and rivaroxaban remotion in cardiothoracic surgery procedures. CytoSorb has also conventional FDA Emergency Use Authorization in the United States for ingest in grown critically stricken COVID-19 patients with close or addicted respiratory failure. CytoSorb is not still authorised in the United States.

The DrugSorb™-ATR antithrombotic remotion system, an investigational figure supported on the aforementioned polymer profession as CytoSorb, has conventional digit FDA Breakthrough Device Designations, digit for the remotion of ticagrelor and added for the remotion of the direct test anticoagulants (DOAC) apixaban and rivaroxaban in a metabolism road journeying during imperative cardiothoracic procedures. The Company has complete the FDA-approved, randomized, dominated STAR-T (Safe and Timely Antithrombotic Removal-Ticagrelor) think of 140 patients at roughly 30 centers in U.S. and Canada to appraise whether intraoperative ingest of DrugSorb-ATR crapper turn the perioperative venture of injury in patients receiving ticagrelor and undergoing cardiothoracic surgery. This important think is witting to hold U.S. bureau and Health Canada marketing support for DrugSorb-ATR in this application.

CytoSorbents’ ceremony technologies are supported on biocompatible, highly porose polymer string that crapper actively vanish cyanogenic substances from murder and added corporeal fluids by pore getting and opencast adsorption. Its technologies hit conventional non-dilutive grant, contract, and added resource of roughly $50 million from DARPA, the U.S. Department of Health and Human Services (HHS), the National Institutes of Health (NIH), National Heart, Lung, and Blood Institute (NHLBI), the U.S. Army, the U.S. Air Force, U.S. Special Operations Command (SOCOM), Air Force Material Command (USAF/AFMC), and others. The Company has numerous marketed products and products low utilization supported upon this unequalled murder ceremony profession fortified by whatever issued U.S. and planetary patents and qualified trademarks, and binary papers applications pending, including ECOS-300CY^®, CytoSorb-XL™, HemoDefend-RBC™, HemoDefend-BGA™, VetResQ^®, K⁺ontrol™, DrugSorb™, ContrastSorb, and others. For more information, gratify meet the Company’s websites at www.cytosorbents.com and www.cytosorb.com or study us on Facebook and X.

Forward-Looking Statements

This apprize promulgation includes forward-looking statements witting to remember for the innocuous nurse from badness ingrained by the Private Securities Litigation Reform Act of 1995. These forward-looking statements include, but are not restricted to, statements most our plans, objectives, forthcoming targets and outlooks for our business, statements most possibleness exposures resulting from our change positions, representations and contentions, and are not arts facts and typically are identified by ingest of cost much as “may,” “should,” “could,” “expect,” “plan,” “anticipate,” “believe,” “estimate,” “predict,” “potential,” “continue” and kindred words, though whatever forward-looking statements are spoken differently. You should be alive that the forward-looking statements in this apprize promulgation equal management’s underway sentiment and expectations, but our actualised results, events and action could dissent materially from those in the forward-looking statements. Factors which could drive or advance to much differences include, but are not restricted to, the risks discussed in our Annual Report on Form 10-K, filed with the SEC on March 14, 2024, as updated by the risks reportable in our Quarterly Reports on Form 10-Q, and in the apprize releases and added subject to shareholders issued by us from instance to instance which endeavor to apprize fascinated parties of the risks and factors which haw change our business. We warn you not to locate unreasonable certainty upon whatever much forward-looking statements. We consent no obligation to publically update or reorganise whatever forward-looking statements, whether as a termination of newborn information, forthcoming events, or otherwise, added than as required low the agent securities laws.

Please Click to Follow Us on Facebook and X

U.S. Company Contact:
Kathleen Bloch, CFO
305 College Road East
Princeton, NJ 08540
+1 (732) 398-5429
kbloch@cytosorbents.com

Investor Relations Contact:
Eric Ribner
LifeSci Advisors, LLC
250 W 55^th St, #3401
New York, NY 10019
+1 (646) 751-4363
ir@cytosorbents.com